Marker Therapeutics (MRKR) Research & Development (2010 - 2026)

Marker Therapeutics (MRKR) has reported Research & Development for 17 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 64.66% year-over-year to $1.5 million in Q2 2026; TTM through Jun 2026 was $8.8 million, a 44.51% decrease from a year earlier, with the FY2025 full-year figure at $11.8 million, down 12.39% from the prior year.
• Research & Development was $1.5 million for Q2 2026 at Marker Therapeutics, down from $2.8 million in the prior quarter.
• Over five years, Research & Development peaked at $7.0 million in Q1 2022 and troughed at $1.5 million in Q2 2026.
• A 5-year average of $3.1 million and a median of $2.7 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development sank 72.78% in 2022 and jumped 94.33% in 2024, its largest moves.
• Over 5 years, Research & Development stood at $2.2 million in 2022, then gained by 19.93% to $2.6 million in 2023, then jumped by 94.33% to $5.1 million in 2024, then tumbled by 57.91% to $2.1 million in 2025, then plunged by 31.05% to $1.5 million in 2026.
• The last three Research & Development figures came in at $1.5 million (Q2 2026), $2.8 million (Q1 2026), and $2.1 million (Q4 2025), per Business Quant data.